氩氦刀冷冻消融治疗老年早期非小细胞肺癌的临床疗效观察  

Clinical study of cryoablation in the treatment of older patients with early stage(Ⅰ/Ⅱ) non-small cell lung cancer

作　　者：邢世江[1] 李新[1] 曾维斌[1] 邓婉芳[1] 许家健[1] 黄萍[1] 

机构地区：[1]南方医科大学附属小榄医院肿瘤科,广东中山528415

出　　处：《现代肿瘤医学》2016年第15期2398-2401,共4页Journal of Modern Oncology

摘　　要：目的：观察氩氦刀冷冻消融治疗老年早期非小细胞肺癌的疗效及安全性。方法：非小细胞肺癌（NSCLC）患者28例,经病理或细胞学确诊,不愿接受手术或无手术适应证的早期（Ⅰ期及部分Ⅱ期）的70岁以上老年患者,全部行CT引导氩氦刀冷冻消融术,观察局部病灶变化、疗效、并发症及生存情况。结果：术后1个月复查CT,按实体瘤评价标准缓解率（CR＋PR）为71.4%（20/28）。术后3个月及6个月评价疗效（CR＋PR）分别为67.9%和64.3%。1~2年随访过程中7例（25.0%）出现转移,其中5例患者出现纵隔淋巴结转移,2例患者出现远处转移,死亡2例,21例（75.0%）患者未见肿瘤复发或转移征象。所有患者均未出现严重并发症。结论：氩氦刀冷冻消融治疗老年早期非小细胞肺癌疗效较好,安全性高,是老年早期NSCLC治疗的新选择,具有较好的临床应用前景。Objective： To observe the clinical efficacy and safety of cryoablation in the treatment of older patients with early stage non- small cell lung cancer（ NSCLC）. Methods： A total of 28 NSCLC older patients（ stage Ⅰ-Ⅱ）received cryoablation. All patients were followed- up for 12 ~ 24 months after operation,using contrast- enhanced CT to evaluate the tumor size and enhancement. Results： After 1 month,according to RECIST criteria,the remission rate（ CR ＋ PR） was 71. 4%. The remission rate after 3 and 6 months was 67. 9% and 64. 3% respectively. The existence rate in one year was 96. 4%. Conclusion： CT- guided percutanous cryoablation may achieve high response rate. It is a simple,safe and reliable procedure for older patients with NSCLC in early stage. It has excellent prospect for clinical applications.

关 键 词：非小细胞肺癌 氩氦刀冷冻消融 治疗 

分 类 号：R734.2[医药卫生—肿瘤]